Anti-osteoporosis drugs and reduction of mortality in cancer patients

被引：0
|
作者：
Chandran, Manju [1 ,2 ,3 ,6 ]
Ching, Lau Tang [4 ,5 ]
机构：
[1] Singapore Gen Hosp, Dept Endocrinol, Osteoporosis & Bone Metab Unit, Singapore, Singapore
[2] Duke NUS Med Sch, Singapore, Singapore
[3] Asia Pacific Consortium Osteoporosis APCO, Singapore, Singapore
[4] Natl Univ Hlth Syst, Dept Rheumatol, Singapore, Singapore
[5] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore
[6] Singapore Gen Hosp, Osteoporosis & Bone Metab Unit, Outram Rd, Singapore 169608, Singapore
来源：
ANNALS ACADEMY OF MEDICINE SINGAPORE | 2024年 / 53卷 / 01期
关键词：
cancer; elderly; mortality; osteoporosis; osteoporotic vertebral fracture; ZOLEDRONIC ACID;
D O I：
10.47102/annals-acadmedsg.20244
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [1] Anti-osteoporosis drugs reduce mortality in cancer patients: A national cohort study of elderly with vertebral fractures
    Huang, Chun-Feng
    Kuo, Tzu-Tung
    Hsu, Jason C.
    Kosik, Russell
    Chan, Wing P.
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2024, 53 (01) : 6 - 14
  • [2] ANTI-OSTEOPOROSIS DRUGS REDUCE MORTALITY IN ELDERLY PATIENTS WITH OR WITHOUT CANCER: A NATIONAL COHORT STUDY OF ADULTS WITH VERTEBRAL FRACTURES
    Huang, C. -F.
    Hsu, J. -C.
    Chan, W. -P.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S157 - S158
  • [3] Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
    Fuggle, N. R.
    Cooper, C.
    Harvey, N. C.
    Al-Daghri, N.
    Brandi, M. -L.
    Bruyere, O.
    Cano, A.
    Dennison, E. M.
    Diez-Perez, A.
    Kaufman, J. -M.
    Palacios, S.
    Prieto-Alhambra, D.
    Rozenberg, S.
    Thomas, T.
    Tremollieres, F.
    Rizzoli, R.
    Kanis, J. A.
    Reginster, J. Y.
    DRUGS, 2020, 80 (15) : 1537 - 1552
  • [4] Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
    N. R. Fuggle
    C. Cooper
    N. C. Harvey
    N. Al-Daghri
    M.-L. Brandi
    O. Bruyere
    A. Cano
    E. M. Dennison
    A. Diez-Perez
    J.-M. Kaufman
    S. Palacios
    D. Prieto-Alhambra
    S. Rozenberg
    T. Thomas
    F. Tremollieres
    R. Rizzoli
    J. A. Kanis
    J. Y. Reginster
    Drugs, 2020, 80 : 1537 - 1552
  • [5] The use of anti-osteoporosis drugs in total knee arthroplasty
    Carulli, Christian
    Civinini, Roberto
    Matassi, Fabrizio
    Villano, Marco
    Innocenti, Massimo
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2011, 23 : 38 - 39
  • [6] Anti-osteoporosis agents
    Jardine, PD
    Thompson, D
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31, 1996, 31 : 211 - 220
  • [7] WHY DID ANTI-OSTEOPOROSIS DRUGS FAIL IN STUDIES OF OSTEOARTHRITIS?
    Lane, N.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S74 - S75
  • [8] OUTCOMES OF CLINICAL TRIALS HAVING ASSESSED ANTI-OSTEOPOROSIS DRUGS IN OSTEOARTHRITIS
    Reginster, J. -Y.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S74 - S74
  • [9] Long-term persistence with anti-osteoporosis drugs after fracture
    Klop, C.
    Welsing, P. M. J.
    Elders, P. J. M.
    Overbeek, J. A.
    Souverein, P. C.
    Burden, A. M.
    van Onzenoort, H. A. W.
    Leufkens, H. G. M.
    Bijlsma, J. W. J.
    de Vries, F.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (06) : 1831 - 1840
  • [10] Long-term persistence with anti-osteoporosis drugs after fracture
    C. Klop
    P. M. J. Welsing
    P. J. M. Elders
    J. A. Overbeek
    P. C. Souverein
    A. M. Burden
    H. A. W. van Onzenoort
    H. G. M. Leufkens
    J. W. J. Bijlsma
    F. de Vries
    Osteoporosis International, 2015, 26 : 1831 - 1840
12345